Stockscreener 앱 받기
2.59
0.38%
-0.01
시간 외 거래:
2.59
전일 마감가:
$2.60
열려 있는:
$2.6
하루 거래량:
59,579
Relative Volume:
0.65
시가총액:
$27.80M
수익:
$62.64M
순이익/손실:
$-24.56M
주가수익비율:
-0.6747
EPS:
-3.8387
순현금흐름:
$-3.70M
1주 성능:
-1.89%
1개월 성능:
+12.12%
6개월 성능:
+6.15%
1년 성능:
+123.28%
1일 변동 폭
$2.57
$2.6351
1주일 범위
$2.54
$2.70
52주 변동 폭
$0.95
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.59 | 27.91M | 62.64M | -24.56M | -3.70M | -3.8387 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | Lake Street | Buy |
| 2025-06-30 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
History Review: What hedge funds are buying Aytu BioPharma Inc2026 Price Momentum & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Aytu BioPharma : Corporate Presentation March 2026 View Presentation Investor Day January 2026 View Presentation - marketscreener.com
Bull Run: Will Aytu BioPharma Inc benefit from rising consumer demand2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Aytu BioPharma, Inc. (AYTU) Competitors - Meyka
Will Aytu BioPharma Inc. stock deliver consistent dividendsJuly 2025 Levels & Consistent Growth Stock Picks - Naître et grandir
Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research - Defense World
AYTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aytu BioPharma AYTU Q2 2026 Earnings Transcript - AOL.com
Is Aytu BioPharma Inc. forming a double bottomGlobal Markets & Intraday High Probability Alerts - mfd.ru
Is Aytu BioPharma Inc. stock a good pick for beginnersJuly 2025 Momentum & Low Risk High Win Rate Stock Picks - mfd.ru
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lytton, foundation report 9.99% Aytu BioPharma (AYTU) stake - Stock Titan
What is the cash position of Aytu BioPharma Inc.2025 Trading Recap & AI Forecasted Entry and Exit Points - mfd.ru
Panic Selling: What analysts say about Aytu BioPharma Inc stockMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
Breakouts Watch: What analysts say about Aytu BioPharma Inc stockMarket Risk Summary & High Accuracy Investment Signals - baoquankhu1.vn
Pharma News: Is Aytu BioPharma Inc. (AY20) stock testing key support2025 Trading Recap & Long-Term Capital Growth Strategies - mfd.ru
Will Aytu BioPharma Inc. (AY20) stock benefit from infrastructure billRisk Management & Consistent Growth Stock Picks - mfd.ru
Is Aytu BioPharma Inc. a strong candidate for buy and hold2025 Macro Impact & Short-Term High Return Ideas - mfd.ru
How Aytu BioPharma Inc. (AY20) stock gains from tech spendingGlobal Markets & Advanced Technical Analysis Signals - mfd.ru
Will Aytu BioPharma Inc. outperform tech stocksShare Buyback & Smart Allocation Stock Tips - mfd.ru
Will Aytu BioPharma Inc. benefit from rising consumer demandJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - mfd.ru
Lake Street Remains a Buy on Aytu BioScience (AYTU) - The Globe and Mail
Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline - simplywall.st
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Yahoo Finance
Aytu BioPharma Q2 Earnings Call Highlights - Defense World
Full Transcript: Aytu BioPharma Q2 2026 Earnings Call - Benzinga
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navi - GuruFocus
Earnings call transcript: Aytu BioPharma Q2 2026 sees revenue dip, stock falls - Investing.com Nigeria
Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costs - ChartMill
AYTU: Exxua launch drives early momentum; net revenue $15.2M, net loss $10.6M on launch costs - TradingView
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
AYTU Reports Q2 Revenue Decline Amid Shift to New Product Launch - GuruFocus
Aytu BioPharma Q2 Earnings Summary & Key Takeaways - Benzinga
Aytu BioPharma Q2 Earnings Assessment - Benzinga
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results - ACCESS Newswire
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada
Earnings To Watch: Aytu BioPharma Inc (AYTU) Reports Q2 2026 Res - GuruFocus
New Strong Sell Stocks for February 2nd - Nasdaq
Earnings Recap: Is Aytu BioPharma Inc stock influenced by commodity pricesProduct Launch & Weekly Market Pulse Alerts - baoquankhu1.vn
Gainers Report: Will Aytu BioPharma Inc stock benefit from M A2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - ACCESS Newswire
Pharma News: Will Aytu BioPharma Inc benefit from rising consumer demandQuarterly Market Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aytu launches EXXUA, first selective 5-HT1A agonist for depression By Investing.com - Investing.com South Africa
Aytu BioPharma Highlights EXXUA Opportunity at Investor Day - TipRanks
Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - ACCESS Newswire
Aytu BioPharma Recaps Investor Day and EXXUA Launch - TradingView
New EXXUA depression drug targets MDD without sexual side effects - Stock Titan
AYTU: Exxua launches as a differentiated MDD therapy, targeting growth with disciplined, scalable execution - TradingView
AYTU: Exxua launches as a novel MDD therapy, targeting unmet needs with strong financial discipline - TradingView
Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):